What's trending, explained.
What's trending, explained.
The Trump administration is moving to make it easier for Americans to get peptide injections that have never been properly tested. On Thursday, October 15, the Department of Health and Human Services submitted an "interim access policy" for compounding using certain peptides to the White House Office of Management and Budget for review, according to the Associated Press. Two people familiar with the plan told the AP it is intended to let specialty pharmacies temporarily compound some of the most popular peptides, including BPC-157, a chemical promoted online to build muscle and heal injuries.
Peptides are short chains of amino acids that trigger hormones involved in growth, metabolism, and healing. Drug companies have turned some into legitimate medicines, but these peptides have not gone through that vetting. They have become popular among people looking to bulk up, look younger, or boost energy — uses the FDA has not approved — and most of the data behind them comes from animal studies. The FDA previously judged BPC-157 and more than a dozen other injectable peptides too risky for pharmacies to compound, citing contamination, allergic reactions, and tumor growth.
The new policy would work through "enforcement discretion": instead of formally declaring the peptides safe for compounding — a federal rulemaking process that takes years and multiple rounds of public comment — the FDA would simply assure pharmacies they will not be targeted for making them. The OMB filing itself gives no specifics.
This is a longtime cause of Health Secretary Robert F. Kennedy Jr. Before joining the administration, he declared that the "FDA's war" on peptides and other wellness products would end; after taking office, he argued that US compounding pharmacies must be allowed to sell peptides because Americans were otherwise turning to "gray market" versions made in China and sold through platforms like TikTok. Earlier this year he directed the agency to reconsider a short list of widely promoted peptides, and in July an FDA advisory panel recommended dropping restrictions on six of the seven peptides put before it — against the conclusion of the FDA's own staff scientists, who said none had been studied enough to establish safety and effectiveness. That panel was selected by Kennedy's health department and included several doctors, pharmacists, and consultants who work in the peptide field.
A formal rule change would require years of review and public comment; an interim policy can reach the market far faster. Analysts estimate the peptide market at $2 to $3 billion, with telehealth companies Hims & Hers and Noom already announcing plans to offer peptides if access eases. Several prominent figures in the Make America Healthy Again movement sell peptide injections themselves, and the proposal was quickly praised online by Kennedy allies in the peptide business.
But the safety questions remain unresolved. The FDA's career scientists have not changed their assessment: contamination, immunogenicity, and inadequate human safety data are still open concerns, and a May survey by physician network Sermo found 95 percent of doctors worried about expanded peptide access, with inadequate medical oversight and safety risks as the top concerns. And enforcement discretion can be reversed by a future administration just as quickly as it was created.
The gray-market argument is the administration's strongest card. Unregulated peptides are already widely available overseas with no quality control, and Kennedy's position is that domestic compounding under some oversight is safer than TikTok-sourced vials from China. Critics answer that legalizing unproven products legitimizes them without establishing they work.
The policy now sits with the Office of Management and Budget, which reviews significant federal regulations. It is not yet clear which peptides will qualify, when it would take effect, or whether the administration still plans the full multi-year rulemaking.
One caution is worth stating plainly: these are unproven products. Peptides like BPC-157 have not been shown safe or effective in rigorous human trials, and the FDA's concerns about contamination and tumor growth have not been resolved. Anyone considering them should talk to a healthcare professional first — and be skeptical of anyone selling a miracle in a vial.